Catalyst Biosciences Total Revenue

Catalyst Biosciences (CBIO) currently reports a total revenue of $-30M as of June 2026. That compares with $150M in the prior-year period — down 119.3% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Catalyst Biosciences's total revenue history and peer comparisons.

Catalyst Biosciences's total revenue decreased from $150M to $-30M — a 119.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Catalyst Biosciences's total revenue of $-30M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Catalyst Biosciences reported $-30M in total revenue as of June 2026. That compares with $150M in the prior-year period — down 119.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Catalyst Biosciences, and consider following CBIO for alerts when major investors trade the stock.